Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FLT PET/CT for Early Response in NSCLC and Thymoma
NCT01610544Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- May 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of fluorothymidine F-18 in non-small cell lung cancer (NSCLC), thymoma, sponsored by National Cancer Institute. Planned start May 2012; status: withdrawn.
02
Drugs
fluorothymidine F-18
03
Conditions
non-small cell lung cancer (NSCLC)thymoma
Beyond the preview
Go deeper on NCT01610544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01610544.